XML 40 R28.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment and Geographic Data (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Reconciliation of Operating Profit (Loss) from Segments to Consolidated |
Segment Results |  |  |  |  |  |  |
| Three Months |  | Nine Months
| 2025 |  | 2024 |  | 2025 |  | 2024
MedSurg and Neurotechnology | $3,803 |  | $3,324 |  | $11,085 |  | $9,636
Orthopaedics | 2,254 |  | 2,170 |  | 6,860 |  | 6,523
Net sales | $6,057 |  | $5,494 |  | $17,945 |  | $16,159
MedSurg and Neurotechnology | $1,426 |  | $1,313 |  | $4,162 |  | $3,838
Orthopaedics | 620 |  | 561 |  | 1,848 |  | 1,728
Cost of sales | $2,046 |  | $1,874 |  | $6,010 |  | $5,566
MedSurg and Neurotechnology | $247 |  | $205 |  | $718 |  | $594
Orthopaedics | 132 |  | 136 |  | 399 |  | 406
Segment research, development and engineering expenses | $379 |  | $341 |  | $1,117 |  | $1,000
MedSurg and Neurotechnology | $972 |  | $780 |  | $2,893 |  | $2,318
Orthopaedics | 742 |  | 760 |  | 2,332 |  | 2,267
Segment selling, general and administrative expenses | $1,714 |  | $1,540 |  | $5,225 |  | $4,585
MedSurg and Neurotechnology | $56 |  | $60 |  | $171 |  | $170
Orthopaedics | 111 |  | 112 |  | 313 |  | 325
Segment depreciation and amortization | $167 |  | $172 |  | $484 |  | $495
Corporate and Other | $48 |  | $40 |  | $127 |  | $118
Amortization of intangible assets | 189 |  | 159 |  | 543 |  | 467
Total depreciation and amortization | $404 |  | $371 |  | $1,154 |  | $1,080
MedSurg and Neurotechnology | $1,102 |  | $966 |  | $3,141 |  | $2,716
Orthopaedics | 649 |  | 601 |  | 1,968 |  | 1,797
Segment operating income | $1,751 |  | $1,567 |  | $5,109 |  | $4,513
Items not allocated to segments: |  |  |  |  |  |  |
Corporate and Other | $(202) |  | $(211) |  | $(670) |  | $(676)
Inventory stepped up to fair value | (61) |  | (29) |  | (160) |  | (38)
Acquisition and integration-related charges | (39) |  | (48) |  | (302) |  | (49)
Amortization of intangible assets | (189) |  | (159) |  | (543) |  | (467)
Structural optimization and other special charges | (41) |  | (22) |  | (93) |  | (92)
Goodwill and other impairments | (73) |  | (2) |  | (163) |  | (21)
Medical device regulation | (11) |  | (13) |  | (30) |  | (41)
Recall-related matters | (1) |  | — |  | (56) |  | (22)
Regulatory and legal matters | — |  | 1 |  | (7) |  | 1
Consolidated operating income | $1,134 |  | $1,084 |  | $3,085 |  | $3,108
Segment Assets |  |
| September 30 |  | December 31
| 2025 |  | 2024
Assets: |  |  |
MedSurg and Neurotechnology | $27,280 |  | $23,115
Orthopaedics | 18,192 |  | 18,507
Total segment assets | $45,472 |  | $41,622
Corporate and Other | 1,585 |  | 1,349
Total assets | $47,057 |  | $42,971
Sales and Other Financial Information by Business Segment |
Segment Capital Spending | Nine Months
| 2025 |  | 2024
Purchases of property, plant and equipment: |  |  |
MedSurg and Neurotechnology | $153 |  | $136
Orthopaedics | 169 |  | 171
Total segment purchases of property, plant and equipment | $322 |  | $307
Corporate and Other | 171 |  | 182
Total purchases of property, plant and equipment | $493 |  | $489

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration